Labiotech.eu - Europe's leading Biotech News Website

Latest Posts

summit therapeutics new antibiotic

More News! 21 Dec 2017

Oxford Biotech Makes a Latin American Deal for Its Antibiotic

In a deal worth up to €23.6M, Summit Therapeutics licensed the commercialization of its new antibiotic ridinilazole to Eurofarma. Oxford-based Summit Therapeutics is working on new antibiotics to fight antimicrobial resistance. Its candidate ridinilazole has attracted the attention of a Brazilian pharma, Eurofarma, and the pair has made a deal for $2.5M (€2.1M) upfront and […]

December 21, 2017 - 1 minutemin - By Evelyn Warner

connected world digital media

Inside Labiotech 21 Dec 2017

How Labiotech is Surfing on the Digital Media Revolution

Media was the first industry to be disrupted by the digital revolution, aka “The Internet”. Most of the established media platforms are still trying to figure out what to do, especially on the revenues/profits side of things. On the other hand, some of the biggest players today were founded in the last 15 years, think […]

December 21, 2017 - 6 minutesmins - By Philip Hemme

uk biotech life science strategy

More News! 21 Dec 2017

Britain’s Life Science Strategy: What UK Biotech Can Do From the Bottom Up

Britain has been making a concerted effort to grow its biotech sector, especially after Brexit. What’s the plan and what can UK biotech do? The last time I walked the the echoey corridors of the Palace of Westminster (UK parliament), I was a wee twelve-year old, on a mission to push forward legislation to prevent […]

December 21, 2017 - 6 minutesmins - By External Contributor

biomx microbiome chronic liver disease

News and Trends 20 Dec 2017

Israeli Biotech Acquires Microbiome Company to Fight Chronic Liver Disease

BiomX has acquired RondinX, expanding its bacterial target discovery platform and adding new microbiome targets for chronic liver disease. BiomX is a company based in Ness Ziona, Israel, developing customized phage therapy to selectively destroy the bacteria that cause diseases ranging from inflammatory bowel disease (IBD) to cancer. The company has just acquired RondinX, another […]

December 20, 2017 - 2 minutesmins - By Clara Rodríguez Fernández

gene therapy orchard therapeutics

News and Trends 20 Dec 2017

British Gene Therapy Gets a Huge £85M Boost in Series B

Orchard Therapeutics has raised a big round of financing to gene therapy options for many rare diseases for which there are no treatments. London-based Orchard Therapeutics has managed to raise £85M (€96M) in Series B, an amount that will certainly give an important boost to its pipeline of gene therapy treatments for rare diseases. The […]

December 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

cancer immunotherapy idorsia roche 1

News and Trends 20 Dec 2017

Actelion Spin Out and Roche Join Forces to Develop Cancer Immunotherapies

Idorsia and Roche have agreed on a research collaboration, with the big pharma getting exclusive rights to develop and license resultant cancer immunotherapy drugs. Idorsia was formed out of J&J’s acquisition of Actelion for €27.9B at the beginning of the year. The spin out, led by Jean-Paul and Martine Clozel, kept hold of Actelion’s drug discovery and early […]

December 20, 2017 - 2 minutesmins - By Alex Dale

ADVERTISEMENT

haldean ventures €100M fund 1

News and Trends 20 Dec 2017

Christmas Has Come Early for Nordic Biotechs as a Norwegian Fund Readies €100M Injection

Hadean Ventures has closed its first fund, which it will begin to invest in life sciences companies around Europe, particularly in the Nordic region. Hadean Ventures is a VC fund based in Oslo, Norway, with the aim of improving healthcare to help patients that are suffering around the world. The VC has closed Hadean Capital […]

December 20, 2017 - 2 minutesmins - By Alex Dale

car t cells regulations

News and Trends 20 Dec 2017

How to Deal with Regulations to Get Approval for CAR-T Cells

The biotech industry is diving into the field of highly individualized gene and cell therapy products. The first CAR-T therapy has just been approved in the US and other breakthrough technologies like mRNA and CRISPR have a foot in the door. But getting to the market is not straightforward, not only for developers but also for […]

December 20, 2017 - 8 minutesmins - By Timothé Cynober

confo roche confobodies neurological 1

News and Trends 19 Dec 2017

Belgian Biotech and Roche Take on Neurological and Developmental Disorders

Confo Therapeutics has joined forces with Roche to develop new small molecule agonists of a G-protein coupled receptor to treat neurological and developmental disorders. Confo Therapeutics is developing a pipeline of G-protein coupled receptor (GPCR)-targeting drugs to address an unmet medical needs. The biotech spun out from the Vrije Universiteit Brussel in 2015 with the backing of […]

December 19, 2017 - 2 minutesmins - By Alex Dale

uniqure gene therapy hemophilia 1

News and Trends 19 Dec 2017

This Gene Therapy for Hemophilia Can Reduce Bleeding by 70%

UniQure has published clinical data revealing that its gene therapy for hemophilia B is effective for years and lets patients stop weekly replacement therapy. From its headquarters in Amsterdam, uniQure is developing what could be one of the first gene therapies for hemophilia. A publication in the journal Blood yesterday details the results of a […]

December 19, 2017 - 3 minutesmins - By Clara Rodríguez Fernández

boehringer ingelheim schizophrenia 1

News and Trends 19 Dec 2017

Schizophrenia and Drug Delivery Biotechs Sign a Major Pharma Partner

Santa Claus is not the only busy one in the weeks leading up to Christmas this year, with Boehringer Ingelheim signing collaborations with Autifony and Evox Therapeutics. In the last couple of days, Boehringer Ingelheim has agreed to collaborate with two exciting British biotechs. On Monday, a deal worth up to €627.5M was agreed with CNS disorders specialist, […]

December 19, 2017 - 2 minutesmins - By Alex Dale

GV Naomi Marcin HEADER 3

News and Trends 19 Dec 2017

Giving Molecular Combing the Golden Coat It Deserves

The novel spin given to some traditional and established technologies can be astounding. They might have been around for decades, applied in the same way over and over again, and yet, at some point, somebody comes along, observes it in a new light and gives it a brand new polish. One such technology is called […]

December 19, 2017 - 5 minutesmins - By External Contributor

ADVERTISEMENT